Take­da chops in­to Ari­ad staff, hand­ing out about 180 pink slips as it re­vamps Boston ops

Christophe We­ber, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Take­da Phar­ma­ceu­ti­cal Co., speaks dur­ing the 18th Nikkei Glob­al Man­age­ment Fo­rum in Tokyo, Japan  (CRED­IT: To­mo­hi­ro Ohsu­mi/Bloomberg via Get­ty Im­ages)

Take­da start­ed the year with a $5.2 bil­lion buy­out of Ari­ad, pay­ing out a huge 74% pre­mi­um to do a deal that raised more than a few eye­brows in the in­dus­try. And now it’s chop­ping up the com­pa­ny it bought in search of the ef­fi­cien­cies it needs to make the num­bers work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER